ARA-290
Erythropoietin-Derived Peptide - Erythropoietin-derived peptide studied for neural repair.
ARA-290 (Cibinetide) is a synthetic peptide derived from the tertiary structure of erythropoietin, studied for its interaction with the innate repair receptor in neuropathic and inflammatory research.
ARA-290 is unusual among the catalog in having advanced into human clinical study, where it was investigated for neuropathic and inflammatory endpoints via the tissue-protective receptor. Its design deliberately separates that repair signaling from erythropoiesis, which is what distinguishes it from erythropoietin itself.
ARA-290 specifications
- CAS number
- 1208243-50-8
- Molecular formula
- C51H54N16O21
- Molecular weight
- 1257.3 g/mol
- Sequence
- 11-amino-acid EPO-derived peptide
- Residues
- 11 residues
- Presentation
- Lyophilized powder
- Documented purity
- 99.89% by HPLC
- Available sizes
- 10mg ($45)
- Archived COA lots
- 3
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Innate repair receptor - Selective study ligand for the tissue-protective receptor complex, without erythropoietic activity.
Reported mechanisms in the literature
- Tissue-protective signaling - Derived from the tertiary structure of erythropoietin, it is a selective study ligand for the innate repair receptor complex, without the erythropoietic (red-cell) activity of EPO. (Brines & Cerami)
What ARA-290 is researched for
- Peripheral nerve - Studied in neuropathic-pain and small-fiber models via the tissue-protective receptor. (Brines & Cerami)
- Immune modulation - Investigated for anti-inflammatory and tissue-protective signaling without erythropoiesis. (Brines & Cerami)
ARA-290 certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| 5R2XJ8 | 3 Oct 2026 | 10mg | Freedom Diagnostics | 99.77% | Confirmed (LC-MS/MS) | COA PDF |
| W6D7E3 | 12 Sep 2026 | 10mg | Freedom Diagnostics | 99.87% | Confirmed (LC-MS/MS) | COA PDF |
| ARA1008212025-02 | 10 Dec 2025 | 10mg | Freedom Diagnostics | 99.89% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on ARA-290
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
Research notes: ARA-290
Background
ARA-290 (cibinetide) is an 11-residue peptide designed from the helix B region of erythropoietin's three-dimensional structure. It was built to keep the tissue-protective signaling of erythropoietin without the effect on red-cell production (Brines et al., 2008). That signaling is attributed to the innate repair receptor, a complex of the erythropoietin receptor and the common beta receptor (CD131) (Brines and Cerami, 2012). ARA-290 has also been examined in published clinical studies in type 2 diabetes with neuropathic symptoms and in sarcoidosis-associated small-fiber loss (Brines et al., 2015; Culver et al., 2017). Those are third-party publications; Aspect Peptides supplies the compound for in-vitro laboratory research only.
What the Aspect certificates show
There are 3 certificate records for the 10mg vial, all from Freedom Diagnostics, dated 10 December 2025 to 3 October 2026. Reported HPLC purity runs from 99.77% to 99.89%. Identity is confirmed by LC-MS/MS, and the appearance is reported as white lyophilized powder. Each full report is available as a PDF on this page and in the COA library.
How it differs from related compounds
Erythropoietin itself is a large glycoprotein; ARA-290 is an 11-residue peptide (molecular weight about 1,257), so it is characterized like a synthetic peptide with a defined mass rather than by potency units. Among the repair-research compounds, BPC-157 and TB-500 are studied through growth-factor and actin-regulation pathways, whereas ARA-290 is studied through the innate repair receptor.
Citations
Brines M et al., Proc Natl Acad Sci U S A 2008 (PMID 18676614). Brines M, Cerami A, Mol Med 2012 (PMID 22183892). Brines M et al., Mol Med 2015 (PMID 25387363). Culver DA et al., Invest Ophthalmol Vis Sci 2017 (PMID 28475703).
Third-party publications are cited for context and are not Aspect Peptides claims. For laboratory research use only.
ARA-290 frequently asked questions
What is ARA-290 (Cibinetide)?
ARA-290, also called Cibinetide, is an 11-amino-acid peptide derived from erythropoietin, studied for its interaction with the innate repair receptor in neuropathic and inflammatory research.
Is ARA-290 an approved drug?
No. It has been studied in clinical trials but has no marketing approval. It is supplied here for in-vitro laboratory research only.
How does it differ from EPO?
It engages the tissue-protective receptor pathway of erythropoietin without stimulating red-blood-cell production, which is the focus of much of its research interest.
Documented to 99.89% purity by HPLC · third-party COA every lot · from $45 · For laboratory research use only.
Related Regenerative & Repair compounds
- BPC-157 - Synthetic pentadecapeptide studied for VEGF and growth-factor receptor signaling.
- TB-500 - Thymosin β-4 fragment studied for actin regulation and tissue repair.
- BPC-157 / TB-500 - Co-formulated repair-research blend in a single vial.
- BPC-157 / TB-500 / KPV - BPC-157, TB-500 and KPV co-formulated in a single vial.
- GHK-Cu - Copper tripeptide studied in skin-remodeling research.
- KPV - α-MSH C-terminal fragment studied for inflammatory signaling.